Massive pseudotumour resection with recombinant factor VIIa (NovoSeven) cover.

This is an interesting case report on the use of rFVIIa in covering surgical resection of a large right gluteal pseudo-tumor in a 32-year-old patient with severe hemophilia A and high-titer inhibitor. Factor VIIa was administered for 72 hours and monitored with measurement of PT and factor VII coagulation activity, and the latter was found […]

Use of recombinant factor VIIa in hereditary bleeding disorders.

This is another excellent review of the mechanism of action, indications, and various doses of rFVIIa (Novoseven) in hereditary bleeding disorders. Its main use has been in patients with factor VIII or IX deficiency with inhibitors, where rFVIIa can by-pass factors VIII or IX, interacts with tissue factor and generates thrombin in addition to activating […]

Recombinant activated factor VII for adjunctive hemorrhage control in trauma.

This is a relatively new area for using rFVIIa, which is to treat uncontrolled haemorrhage in patients with severe trauma, following the earlier report of using rFVIIa successfully in treating bleeding in a soldier who suffered with bullet injur (Kenet et al., Lancet 1999;354:1879). rFVIIa was effective in controlling bleeding and resulted in significant reduction […]